{"id":"W3102615618","doi":"10.25251/skin.4.supp.82","title":"Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study","year":2020,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma; AstraZeneca","keywords":"Ustekinumab; Double blinded; Medicine; Placebo; Plaque psoriasis; Psoriasis; Dermatology; Randomized controlled trial; Internal medicine; Pathology; Disease; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255164,0.0003545296,0.001921615,0.0002142652,0.0001306043,0.00001202415,0.0002494889,0.0001465956,0.00005854788],"category_scores_gemma":[0.0006286766,0.0001803056,0.00008616728,0.0002388014,0.0002541456,0.00007756795,0.00006957525,0.000376739,0.000005131268],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003970085,"about_ca_system_score_gemma":0.00009387828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002217814,"about_ca_topic_score_gemma":0.0001453554,"domain_scores_codex":[0.996741,0.001140225,0.001334286,0.000296803,0.0002151693,0.0002725485],"domain_scores_gemma":[0.9956234,0.002913432,0.0008903405,0.0002447443,0.0002081436,0.0001199032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9652251,0.001073356,0.0003466573,0.00001190539,0.002626725,0.0001862317,0.022668,0.0003423696,0.0005388965,0.000003697474,0.0002660111,0.006711028],"study_design_scores_gemma":[0.981768,0.0102734,0.0007234898,0.0003167861,0.002594713,0.0004092016,0.002915128,0.00004493076,0.0006080171,0.00003118023,0.0001253077,0.0001898947],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924064,0.001802625,0.00006381857,0.0023973,0.0002520446,0.002833629,0.0001435841,0.00001033965,0.00009023092],"genre_scores_gemma":[0.9989914,0.0004572872,0.00006916904,0.0002418134,0.0001135449,0.00001638755,0.00003467835,0.0000238003,0.00005193898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01975287,"threshold_uncertainty_score":0.7352648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01981299134265906,"score_gpt":0.255535521771845,"score_spread":0.2357225304291859,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}